


## Trilostane

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-14281   |
| CAS No.:           | 13647-35-3   |
| Molecular Formula: | C <sub>20</sub> H <sub>27</sub> NO <sub>3</sub>  |
| Molecular Weight:  | 329.43   |
| Target:            | Others   |
| Pathway:           | Others   |
| Storage:           | Powder    -20°C    3 years<br>4°C    2 years<br>In solvent   -80°C    2 years<br>-20°C    1 year |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 56 mg/mL (169.99 mM)  
 \* "≥" means soluble, but saturation unknown.

|                              | Solvent<br>Concentration | Mass | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|--------------------------|------|-----------|------------|------------|
|                              |                          |      |           |            |            |
| Preparing<br>Stock Solutions | 1 mM                     |      | 3.0355 mL | 15.1777 mL | 30.3555 mL |
|                              | 5 mM                     |      | 0.6071 mL | 3.0355 mL  | 6.0711 mL  |
|                              | 10 mM                    |      | 0.3036 mL | 1.5178 mL  | 3.0355 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: 2.5 mg/mL (7.59 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: 2.5 mg/mL (7.59 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Trilostane (Win 24540) is a competitive and orally active 3-β-hydroxysteroiddehydrogenase (3β-HSD) inhibitor. Trilostane is a synthetic nonhormonal steroid. Trilostane can be used for the research of breast cancer and prostate cancer<sup>[1][2]</sup>.

#### In Vitro

Trilostane dose- and time-dependently influences pregnenolone metabolism in adrenal cortex<sup>[2]</sup>.  
 Trilostane selectively inhibits pregnenolone converts to progesterone in adrenal gland<sup>[2]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

Trilostane (5.3-50 mg/kg; oral administration, once daily for 3 months) controls pituitary-dependent hyperadreno corticism in dogs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

|                 |   |
|-----------------|---|
| Animal Model:   | Dogs with naturally-occurring pituitary-dependent hyperadrenocorticism (PDH) <sup>[1]</sup> |
| Dosage:         | 5.3-50 mg/kg  |
| Administration: | Oral administration; 5.3-50 mg/kg, once daily for 3 months                                  |
| Result:         | Effectively achieved endocrine control with safe effects and free of side-effects.          |

## CUSTOMER VALIDATION

- Leukemia. 2021 Mar 8.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. JA Braddock, et al. Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Veterinary Journal. 10 March 2008.

[2]. Ouschan C, et al. The influence of trilostane on steroid hormone metabolism in canine adrenal glands and corpora lutea-an in vitro study. Vet Res Commun. 2012 Mar;36(1):35-40.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA